Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2007 1
2009 3
2010 1
2011 2
2012 1
2013 2
2014 3
2015 2
2016 1
2020 1
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis.
Abdel-Rahman O, ElHalawani H, Ahmed H. Abdel-Rahman O, et al. Future Oncol. 2015;11(24):3307-19. doi: 10.2217/fon.15.265. Epub 2015 Nov 12. Future Oncol. 2015. PMID: 26561878 Review.

The relative risk of all-grade skin rash and acneiform dermatitis was 1.71 (95% CI: 1.07-2.72; p = 0.02) and 6.55 (95% CI: 3.42-12.56; p < 0.00001), correspondingly; while the relative risk of high-grade skin rash and acneiform dermatitis was 2.64 (

…
The relative risk of all-grade skin rash and acneiform dermatitis was 1.71 (95% CI: 1.07-2.72; p = 0.02) and 6.55 (95% CI: 3.4 …
Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON study.
Brueckl WM, Reck M, Schäfer H, Neben K, Griesinger F, Rawluk J, Krüger S, Kokowski K, Ficker JH, Möller M, Schueler A, Laack E. Brueckl WM, et al. J Geriatr Oncol. 2023 Jan;14(1):101394. doi: 10.1016/j.jgo.2022.10.009. Epub 2022 Oct 30. J Geriatr Oncol. 2023. PMID: 36323612 Free article.
In the 70 years age group and the <70 years age group, grade 3 adverse drug reactions (ADRs) were observed in 34.8% and 40.7% of patients, respectively; the most common were diarrhea (13.6% and 14.0%), acneiform dermatitis (7.6% and 7.0%), stomatitis (1.5% and 4. …
In the 70 years age group and the <70 years age group, grade 3 adverse drug reactions (ADRs) were observed in 34.8% and 40.7% of patients …
Results of the non-small cell lung cancer part of a phase III, open-label, randomized trial evaluating topical corticosteroid therapy for facial acneiform dermatitis induced by EGFR inhibitors: stepwise rank down from potent corticosteroid (FAEISS study, NCCH-1512).
Nishino K, Fujiwara Y, Ohe Y, Saito R, Miyauchi E, Kobayashi T, Nakai Y, Takahashi T, Shibata T, Hamaguchi T, Kikuchi K, Yamazaki N, Fukuda H, Nozawa K, Kiyohara Y. Nishino K, et al. Support Care Cancer. 2021 May;29(5):2327-2334. doi: 10.1007/s00520-020-05765-7. Epub 2020 Sep 11. Support Care Cancer. 2021. PMID: 32918131 Free PMC article. Clinical Trial.
Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors.
Doi T, Ohtsu A, Tahara M, Tamura T, Shirao K, Yamada Y, Otani S, Yang BB, Ohkura M, Ohtsu T. Doi T, et al. Int J Clin Oncol. 2009 Aug;14(4):307-14. doi: 10.1007/s10147-008-0855-2. Epub 2009 Aug 25. Int J Clin Oncol. 2009. PMID: 19705240 Clinical Trial.
Seven patients had grade-3/4 adverse events; fatigue and anorexia were most common. The most common skin toxicities were rash and acneiform dermatitis. No neutralizing anti-panitumumab antibodies were detected. ...
Seven patients had grade-3/4 adverse events; fatigue and anorexia were most common. The most common skin toxicities were rash and acneifo …
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, Dummer R. Ascierto PA, et al. Lancet Oncol. 2013 Mar;14(3):249-56. doi: 10.1016/S1470-2045(13)70024-X. Epub 2013 Feb 13. Lancet Oncol. 2013. PMID: 23414587 Clinical Trial.
Six (20%) of 30 patients with NRAS-mutated melanoma had a partial response (three confirmed) as did eight (20%) of 41 patients with BRAF-mutated melanoma (two confirmed). The most frequent adverse events were acneiform dermatitis (18 [60%] patients with NRAS -mutate …
Six (20%) of 30 patients with NRAS-mutated melanoma had a partial response (three confirmed) as did eight (20%) of 41 patients with BRAF-mut …
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.
Zimmer L, Barlesi F, Martinez-Garcia M, Dieras V, Schellens JH, Spano JP, Middleton MR, Calvo E, Paz-Ares L, Larkin J, Pacey S, Venturi M, Kraeber-Bodéré F, Tessier JJ, Eberhardt WE, Paques M, Guarin E, Meresse V, Soria JC. Zimmer L, et al. Clin Cancer Res. 2014 Aug 15;20(16):4251-61. doi: 10.1158/1078-0432.CCR-14-0341. Epub 2014 Jun 19. Clin Cancer Res. 2014. PMID: 24947927 Clinical Trial.
RESULTS: Ninety-five patients received RO4987655, including 18 BRAF-mutant melanoma, 23 BRAF wild-type melanoma, 24 KRAS-mutant NSCLC, and 30 KRAS-mutant colorectal cancer. Most frequent adverse events were rash, acneiform dermatitis, and gastrointestinal disorders, …
RESULTS: Ninety-five patients received RO4987655, including 18 BRAF-mutant melanoma, 23 BRAF wild-type melanoma, 24 KRAS-mutant NSCLC, and 3 …
Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy.
Passarini B, Infusino SD, Barbieri E, Varotti E, Gionchetti P, Rizzello F, Morselli C, Tambasco R, Campieri M. Passarini B, et al. Dermatology. 2007;215(4):295-300. doi: 10.1159/000107622. Dermatology. 2007. PMID: 17911986
The cutaneous manifestations due to drugs were further divided into three groups: rosacea, acneiform dermatitis and psoriasis-like dermatitis. The most notable aspect of our series is the high number of patients presenting psoriasiform-type dermatitides with a gener …
The cutaneous manifestations due to drugs were further divided into three groups: rosacea, acneiform dermatitis and psoriasis- …
FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer.
Giusti RM, Cohen MH, Keegan P, Pazdur R. Giusti RM, et al. Oncologist. 2009 Mar;14(3):284-90. doi: 10.1634/theoncologist.2008-0254. Epub 2009 Mar 12. Oncologist. 2009. PMID: 19282350 Free article. Clinical Trial.
Grade 3 and 4 AEs occurring more commonly in panitumumab-treated patients included rash/acneiform dermatitis, diarrhea, dehydration, primarily resulting from diarrhea, hypokalemia, stomatitis/mucositis, and pulmonary embolism. ...
Grade 3 and 4 AEs occurring more commonly in panitumumab-treated patients included rash/acneiform dermatitis, diarrhea, dehydr …
Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers.
Hughes AN, O'Brien ME, Petty WJ, Chick JB, Rankin E, Woll PJ, Dunlop D, Nicolson M, Boinpally R, Wolf J, Price A. Hughes AN, et al. J Clin Oncol. 2009 Mar 10;27(8):1220-6. doi: 10.1200/JCO.2008.19.3995. Epub 2009 Jan 21. J Clin Oncol. 2009. PMID: 19164205 Free PMC article. Clinical Trial.
DLT was observed in one of six patients at 300 mg (rash) and two of five patients at 350 mg (acneiform dermatitis and fatigue/decreased Eastern Cooperative Oncology Group performance status). ...
DLT was observed in one of six patients at 300 mg (rash) and two of five patients at 350 mg (acneiform dermatitis and fatigue/ …
Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months.
van Vollenhoven RF, Morabito LM, Engleman EG, McGuire JL. van Vollenhoven RF, et al. J Rheumatol. 1998 Feb;25(2):285-9. J Rheumatol. 1998. PMID: 9489820 Clinical Trial.
Thirty-four patients (68%) completed 6 months of treatment and 21 patients (42%) completed 12 months. Mild acneiform dermatitis was the most common adverse event (54%). Pre and postmenopausal women experienced similar efficacy and adverse effects from DHEA. ...
Thirty-four patients (68%) completed 6 months of treatment and 21 patients (42%) completed 12 months. Mild acneiform dermatitis …
16 results